Vertex Pharmaceuticals (VRTX -0.96%) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time curative gene editing treatment for blood disorders sickle cell disease and beta thalassemia. And Vertex recently reported positive data from trials of its pain management candidate and aims to file for regulatory review this year. All of this is great and could result in billions of dollars in revenue. But Vertex also ...